Deerfield Mgmt IV, L.P.'s Net Worth

$1.93 Billion

Who is Deerfield Mgmt IV, L.P.?

Deerfield Mgmt IV, L.P. has an estimated net worth of $1.93 Billion. This is based on reported shares across multiple companies, which include Oncology Institute, Inc., Nkarta, Inc., Revolution Medicines, Inc., Singular Genomics Systems, Inc., Edgewise Therapeutics, Inc., Nuvalent, Inc., Mirum Pharmaceuticals, Inc., ARVINAS INC., Schrodinger, Inc., AdaptHealth Corp., Larimar Therapeutics, Inc., PROTEON THERAPEUTICS INC, Cabaletta Bio, Inc., Annexon, Inc., Frequency Therapeutics, Inc., and ARS Pharmaceuticals, Inc..

SEC CIK

Deerfield Mgmt IV, L.P.'s CIK is 0001713467

Past Insider Trading and Trends

2021 was Deerfield Mgmt IV, L.P.'s most active year for acquiring shares with 27 total transactions. Deerfield Mgmt IV, L.P.'s most active month to acquire stocks was the month of June. 2021 was Deerfield Mgmt IV, L.P.'s most active year for disposing of shares, totalling 20 transactions. Deerfield Mgmt IV, L.P.'s most active month to dispose stocks was the month of June. 2019 saw Deerfield Mgmt IV, L.P. paying a total of $140,679,996.00 for 18,708,852 shares, this is the most they've acquired in one year. In 2021 Deerfield Mgmt IV, L.P. cashed out on 139,014,036 shares for a total of $2,656,549.79, their largest year based on trade value.